Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT-Stromal and Tgfβ-Dependent Mechanisms

Mol Cancer Ther. 2022 Nov 3;21(11):1729-1741. doi: 10.1158/1535-7163.MCT-22-0130.

Abstract

Most patients with bladder cancer do not respond to ICB targeting of the PD-L1 signaling axis. Our modeling applied a de novo resistance signature to show that tumor-infiltrating myeloid cells promote poor treatment response in a TGFβ-dependent mechanism.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • B7-H1 Antigen* / genetics
  • Humans
  • Lymphocytes, Tumor-Infiltrating
  • Myeloid Cells
  • Signal Transduction
  • Transforming Growth Factor beta
  • Tumor Microenvironment
  • Urinary Bladder Neoplasms*

Substances

  • B7-H1 Antigen
  • Transforming Growth Factor beta